Nnyefe ọgwụ ezubere iche maka ụlọọgwụ ọrịa kansa

Nnyefe ọgwụ ezubere iche maka ụlọ ọgwụ ọrịa kansa: Ịkwalite ịdị irè ọgwụgwọ Ezubere usoro nnyefe ọgwụ ezubere na-agbanwe ọgwụgwọ ọrịa kansa, na-enye arụmọrụ ka mma yana mbelata mmetụta ndị ọrịa. Edemede a na-enyocha ụzọ dị iche iche eji eme ya nnyefe ọgwụ ezubere iche maka ụlọ ọgwụ kansa, na-enyocha usoro ha, uru na ihe ịma aka ha. Anyị ga-enyocha n'ime ihe atụ ndị akọwapụtara ma tụlee ọdịnihu nke ngalaba a dị oke mkpa na oncology.

Ịghọta nnyefe ọgwụ ezubere iche

Kedu ihe bụ nnyefe ọgwụ ezubere iche?

N'adịghị ka chemotherapy ọdịnala, nke na-ekesa ọgwụ n'ahụ niile. nnyefe ọgwụ ezubere iche maka ụlọ ọgwụ kansa na-elekwasị anya na ibuga ọgwụ ọgwụgwọ ozugbo na mkpụrụ ndụ kansa. Ụzọ a na-ebelata mmebi nke anụ ahụ dị mma, na-eduga ná mmetụta dị ole na ole na ọgwụgwọ ọgwụgwọ ka mma. A na-eji ụzọ dị iche iche eme ihe iji nweta nnyefe a ezubere iche, nke ọ bụla nwere njirimara na ngwa pụrụ iche.

Usoro nke nnyefe ọgwụ ezubere iche

Ọtụtụ usoro na-akwado nnyefe ọgwụ ezubere iche maka ụlọ ọgwụ kansa. Ndị a gụnyere:

• Njikọ ọgwụ mgbochi-ọgwụ (ADC): Ọgwụ mgbochi ọrịa na-ejikọta kpọmkwem na mkpụrụ ndụ kansa, na-ebu ọgwụ ahụ agbakwunyere ozugbo na etuto ahụ.
• Nnyefe ọgwụ liposomal: A na-etinye ọgwụ n'ime liposomes, bụ nke a na-elekwasị anya na mkpụrụ ndụ kansa site na iji ligands ma ọ bụ ọgwụ mgbochi.
• nnyefe ọgwụ nanoparticle: Enwere ike ịmepụta nanoparticles ka ọ buru ọgwụ gaa na saịtị etuto ahụ, nwere ike iji mmetụta nkwalite na njigide (EPR) emelitere.
• Ndị nanoparticles ezubere iche: Ndị a na-eji mgbanwe elu dị ka ligands ma ọ bụ ọgwụ mgbochi maka ichekwa mkpụrụ ndụ tumor.

Ụdị usoro nnyefe ọgwụ ezubere iche

Njikọ Antibody-Drug Conjugates (ADCs)

ADC bụ ihe atụ ama ama nke nnyefe ọgwụ ezubere iche maka ụlọ ọgwụ kansa. Ha na-ejikọta nkọwa nke ọgwụ mgbochi monoclonal na ike nke ọgwụ cytotoxic. Usoro a na-eme ka ọ dị mma site na ibuga ọgwụ ahụ ozugbo na mkpụrụ ndụ kansa, na-echekwa anụ ahụ dị mma. Dịka ọmụmaatụ, trastuzumab emtansine (Kadcyla) bụ ADC eji agwọ ọrịa kansa ara nke nwere HER2.¹

Nnyefe ọgwụ Liposomal

Liposomes na-ekpuchi ọgwụ ahụ, na-echebe ya pụọ ​​na mmebi na ịbawanye oge mgbasa ya n'ime ọbara. pharmacokinetics a ka mma na-enye ohere maka nnyefe ezubere iche na mkpụrụ ndụ tumo site na ligands ezubere iche ma ọ bụ mkpokọta na-agafe agafe site na mmetụta EPR. Doxorubicin liposomes (dịka ọmụmaatụ, Doxil) bụ ihe atụ nke ụlọ ọgwụ kwadoro.²

Uru na ihe ịma aka nke nnyefe ọgwụ ezubere iche

Ọdịnihu nke nnyefe ọgwụ ezubere iche maka ụlọọgwụ ọrịa kansa

Nnyocha na-aga n'ihu na-emeziwanye ma gbasaa ohere nke nnyefe ọgwụ ezubere iche maka ụlọ ọgwụ kansa. Ọganihu na nanotechnology, genomics, na onyogho na-eduga n'ịzụlite usoro ọkaibe na nke dị irè karị. Ijikọta ọgwụ ahaziri onwe ya na iji usoro ọgwụgwọ ngwakọta na-emeghekwa ụzọ maka nsonaazụ ka mma na ọgwụgwọ ọrịa kansa. Maka ozi ndị ọzọ gbasara ọgwụgwọ ọrịa kansa dị elu na nyocha, gaa na ya Shandong Baofa Cancer Research Institute.

¹ FDA. (n.d.). Kadcyla (trastuzumab emtansine). Ewepụtara na [https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm361642.htm](https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm361642.htm)

² FDA. (n.d.). DOXIL (doxorubicin HCl liposomal injection). Eweghachitere na [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020515](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&Appl15)